Teva Pharmaceutical Finance II B.V., founded in 2007 and based in the Netherlands, serves as a finance subsidiary of Teva Pharmaceutical Industries Ltd., a global leader in generic pharmaceuticals. The company primarily focuses on raising capital through debt instruments to support its parent company’s ongoing operations and strategic initiatives.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| TEVA 1.88% 2027-03-31 EURTeva Pharmaceutical Finance II B.V. | Ireland | 2027-03-31 | 1.875 | 3.20 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Teva Pharmaceutical Finance II B.V. has been active in the bond market, with its first bond issuance occurring shortly after its establishment in 2007. Significant issuances include a substantial $2 billion bond in 2019, aimed at refinancing existing debts, along with various tranches of notes that feature competitive yields compared to industry peers. Current bond yields from Teva Finance are notably in the range of 4% to 6%, reflecting the broader market conditions. Recent notable developments include a shift in credit ratings that may influence future bond performances and investor interest, underscoring the dynamic nature of their capital structure amidst ongoing market volatility.